Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer

Trial Profile

Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Onalespib (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 May 2018 Planned number of patients changed from 24 to 33.
    • 14 May 2018 Planned primary completion date changed from 1 Jan 2018 to 31 Dec 2019.
    • 01 Aug 2017 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top